Form D · Biotechnology
Transposagen Biopharmaceuticals, Inc.
Lexington, KY · CIK 0001537601
Offering snapshot reported Jul 18, 2012 · SEC filing
- Reported sold
- $355K Offering amount: $1.28M
- Investors reported
- 7 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jul 17, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 18, 2012 | Initial | $355,000 | No comparison | 7 | SEC filing |
| Dec 20, 2011 | Initial | $725,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-181466
Source: Form D, filed Jul 18, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Eric M. Ostertag | Director, Executive |
| Joseph Ruiz | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
145 Graham Avenue Suite A217
Lexington, KY, 40506
Lexington, KY, 40506